TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Apixaban for the Prevention of Venous Thromboembolism in High-Risk Ambulatory Cancer Patients: A Randomized Placebo-Controlled, Double-Blind Clinical Trial
Brief Summary: Cancer patients have an increased risk of developing blood clots in the veins compared to non-cancer patients. Cancer patients who develop blood clots can lead to reduced life expectancy, delayed cancer treatment, and decreased quality of life. Prevention is the most effective way to decrease the complications associated with blood clots in the veins. Although previous clinical trials have shown some benefit on the use of medication to prevent blood clots in the veins in ambulatory cancer patients, these studies have been inconclusive in demonstrating that existing blood thinners significantly reduce the rate of blood clots in cancer patients. One possible explanation relates to the fact that these studies have included a large proportion of cancer patients who are a low risk of developing blood clots in the veins. We are proposing to identify cancer patients who are at a high risk of developing blood clots by using a validated tool at the time of their cancer diagnosis. The identified high risk cancer patients will be asked to participate in a trial to test the safety and efficacy of a new oral medication that has been used to prevent blood clots in patients undergoing surgery. We are enrolling 574 patients in 7 Canadian centers (Ottawa, Halifax, Montreal, Vancouver, Sault Ste. Marie, Toronto and Hamilton). 287 patients will receive the study drug and 287 will receive an inactive substance. Analysis will be performed to assess the safety and the superiority of the study drug.


Options:
A: Arm Label: Apixaban; Type: ACTIVE_COMPARATOR; Interventions: Drug: Apixaban | Arm Label: Placebo drug; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo drug | Intervention Type: DRUG; Name: Apixaban; Assigned to Arm(s): Apixaban | Intervention Type: DRUG; Name: Placebo drug; Assigned to Arm(s): Placebo drug
B: Intervention Type: DRUG; Name: dalteparin; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: quality-of-life assessment; Assigned to Arm(s): N/A
C: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tinzaparin sodium 100 UI/Kg/OD for 12 weeks | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: Tinzaparin sodium 100 UI/Kg/OD for 12 weeks | Intervention Type: DRUG; Name: Tinzaparin sodium 100 UI/Kg/OD for 12 weeks; Assigned to Arm(s): A, B
D: Arm Label: Rivaroxaban; Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban | Arm Label: Placebo; Type: EXPERIMENTAL; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Rivaroxaban; Assigned to Arm(s): Rivaroxaban | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Is There a Difference in Pain and Quality of Life Following Vaginal Hysterectomy With Vaginal Reconstruction Compared to Robotic Colpopexy? A Prospective Cohort Study
Brief Summary: The purpose of this study is to to determine if there is a difference in patient related outcomes of pain and quality of life following vaginal hysterectomy with vaginal prolapse repair compared to robotic-assisted repair.

We hypothesize that pain and quality of life following robotic-assisted repair will be similar to that following vaginal reconstruction, when performed in conjunction with vaginal hysterectomy.


Options:
A: Arm Label: Robot-assisted; Type: EXPERIMENTAL; Interventions: Procedure: Hysterectomy | Arm Label: Laparoscopic Hysterectomy; Type: EXPERIMENTAL; Interventions: Procedure: Hysterectomy | Intervention Type: PROCEDURE; Name: Hysterectomy; Assigned to Arm(s): Laparoscopic Hysterectomy, Robot-assisted
B: Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: robotic laparoscopic sacrocolpopexy | Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Laparoscopic Sacral Colpopexy | Intervention Type: PROCEDURE; Name: robotic laparoscopic sacrocolpopexy; Assigned to Arm(s): 2 | Intervention Type: PROCEDURE; Name: Laparoscopic Sacral Colpopexy; Assigned to Arm(s): 1
C: Arm Label: Robot assisted laparoscopic hysterectomy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Robot assisted laparoscopic hysterectomy | Arm Label: Abdominal hysterectomy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Abdominal hysterectomy | Intervention Type: PROCEDURE; Name: Abdominal hysterectomy; Assigned to Arm(s): Abdominal hysterectomy | Intervention Type: PROCEDURE; Name: Robot assisted laparoscopic hysterectomy; Assigned to Arm(s): Robot assisted laparoscopic hysterectomy
D: Arm Label: Robotic-assisted prolapse repair; Type: N/A; Interventions: N/A | Arm Label: Vaginal prolapse repair; Type: N/A; Interventions: N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy and Safety of "as Required" Sildenafil for Patients With Moderate to Severe Raynaud's Phenomenon (RP)
Brief Summary: The purpose of this study is to determine whether "on-demand" sildenafil is effective in the treatment of Raynaud's phenomenon.


Options:
A: Arm Label: Sildenafil 80 mg; Type: EXPERIMENTAL; Interventions: Drug: Sildenafil 80 mg | Arm Label: Sildenafil 40 mg; Type: EXPERIMENTAL; Interventions: Drug: Sildenafil 40 mg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Sildenafil 40 mg; Assigned to Arm(s): Sildenafil 40 mg | Intervention Type: DRUG; Name: Sildenafil 80 mg; Assigned to Arm(s): Sildenafil 80 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Amlodipine-Udenafil (AU) arm; Type: EXPERIMENTAL; Interventions: Drug: Udenafil or Amlodipine | Arm Label: Udenafil-Amlodipine (UA) arm; Type: EXPERIMENTAL; Interventions: Drug: Udenafil or Amlodipine | Intervention Type: DRUG; Name: Udenafil or Amlodipine; Assigned to Arm(s): Amlodipine-Udenafil (AU) arm, Udenafil-Amlodipine (UA) arm
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Tadalafil | Intervention Type: DRUG; Name: Tadalafil; Assigned to Arm(s): Placebo
D: Arm Label: Vardenafil 10 mg bid; Type: EXPERIMENTAL; Interventions: Drug: vardenafil, Drug: Placebo | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: vardenafil, Drug: Placebo | Intervention Type: DRUG; Name: vardenafil; Assigned to Arm(s): Placebo, Vardenafil 10 mg bid | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo, Vardenafil 10 mg bid

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Controlled Trial of BiPhasic Nasal Continuous Positive Airway Pressure (BP-NCPAP) vs. Non-invasive High Frequency Ventilation (NIHFV) Following NCPAP Failure: A Pilot Study
Brief Summary: In preterm infants, endotracheal mechanical ventilation is well known to cause various forms of lung injury including volutrauma, barotrauma and oxytrauma - collectively known as ventilator-induced lung injury (VILI). As such, there is a move towards non-invasive ventilation (NIV) in recent decades. However, many infants placed on NIV modes fail and require intubation. A relatively recent mode of NIV is non-invasive high frequency ventilation (NIHFV). Studies on this modality are scarce, but do suggest that neonates can be ventilated effectively. However, its efficacy in comparison with other existing modes of NIV remains unknown due to lack of appropriate studies. The investigators hypothesize that NIHFV is a superior NIV mode than Biphasic Nasal Continuous Positive Airway Pressure (BP-NCPAP) in preterm infants in preventing intubation following NCPAP failure.


Options:
A: Arm Label: nHFOV; Type: EXPERIMENTAL; Interventions: Device: nHFOV | Arm Label: nCPAP; Type: ACTIVE_COMPARATOR; Interventions: Device: nCPAP | Intervention Type: DEVICE; Name: nHFOV; Assigned to Arm(s): nHFOV | Intervention Type: DEVICE; Name: nCPAP; Assigned to Arm(s): nCPAP
B: Arm Label: BP-NCPAP; Type: ACTIVE_COMPARATOR; Interventions: Device: BP-NCPAP | Arm Label: NIHFV; Type: EXPERIMENTAL; Interventions: Device: NIHFV | Intervention Type: DEVICE; Name: BP-NCPAP; Assigned to Arm(s): BP-NCPAP | Intervention Type: DEVICE; Name: NIHFV; Assigned to Arm(s): NIHFV
C: Arm Label: nHFPV; Type: EXPERIMENTAL; Interventions: Procedure: Intrapulmonary Percussive Ventilation | Arm Label: nCPAP; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Nasal Continuous Positive Airway Pressure ventilation | Intervention Type: PROCEDURE; Name: Nasal Continuous Positive Airway Pressure ventilation; Assigned to Arm(s): nCPAP | Intervention Type: PROCEDURE; Name: Intrapulmonary Percussive Ventilation; Assigned to Arm(s): nHFPV
D: Arm Label: NHFOV; Type: EXPERIMENTAL; Interventions: Device: NHFOV | Arm Label: NCPAP; Type: ACTIVE_COMPARATOR; Interventions: Device: NCPAP | Intervention Type: DEVICE; Name: NHFOV; Assigned to Arm(s): NHFOV | Intervention Type: DEVICE; Name: NCPAP; Assigned to Arm(s): NCPAP

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Controlled Trial of BiPhasic Nasal Continuous Positive Airway Pressure (BP-NCPAP) vs. Non-invasive High Frequency Ventilation (NIHFV) Following NCPAP Failure: A Pilot Study
Brief Summary: In preterm infants, endotracheal mechanical ventilation is well known to cause various forms of lung injury including volutrauma, barotrauma and oxytrauma - collectively known as ventilator-induced lung injury (VILI). As such, there is a move towards non-invasive ventilation (NIV) in recent decades. However, many infants placed on NIV modes fail and require intubation. A relatively recent mode of NIV is non-invasive high frequency ventilation (NIHFV). Studies on this modality are scarce, but do suggest that neonates can be ventilated effectively. However, its efficacy in comparison with other existing modes of NIV remains unknown due to lack of appropriate studies. The investigators hypothesize that NIHFV is a superior NIV mode than Biphasic Nasal Continuous Positive Airway Pressure (BP-NCPAP) in preterm infants in preventing intubation following NCPAP failure.


Options:
A: Arm Label: Nasal Continuous Positive Airway Pressure (CPAP); Type: ACTIVE_COMPARATOR; Interventions: Device: Nasal CPAP (SLE) | Arm Label: Nasal Intermittent Mandatory Ventilation (IMV); Type: ACTIVE_COMPARATOR; Interventions: Device: Nasal IMV (SLE) | Intervention Type: DEVICE; Name: Nasal CPAP (SLE); Assigned to Arm(s): Nasal Continuous Positive Airway Pressure (CPAP) | Intervention Type: DEVICE; Name: Nasal IMV (SLE); Assigned to Arm(s): Nasal Intermittent Mandatory Ventilation (IMV)
B: Arm Label: BP-NCPAP; Type: ACTIVE_COMPARATOR; Interventions: Device: BP-NCPAP | Arm Label: NIHFV; Type: EXPERIMENTAL; Interventions: Device: NIHFV | Intervention Type: DEVICE; Name: BP-NCPAP; Assigned to Arm(s): BP-NCPAP | Intervention Type: DEVICE; Name: NIHFV; Assigned to Arm(s): NIHFV
C: Arm Label: NAVA-PS; Type: EXPERIMENTAL; Interventions: Device: noninvasive respiratory support with NAVA mode and PSV | Arm Label: PS-NAVA; Type: EXPERIMENTAL; Interventions: Device: noninvasive respiratory support with NAVA mode and PSV | Intervention Type: DEVICE; Name: noninvasive respiratory support with NAVA mode and PSV; Assigned to Arm(s): NAVA-PS, PS-NAVA
D: Arm Label: NHFOV; Type: EXPERIMENTAL; Interventions: Device: NHFOV | Arm Label: NCPAP; Type: ACTIVE_COMPARATOR; Interventions: Device: NCPAP | Arm Label: NIPPV; Type: EXPERIMENTAL; Interventions: Device: NIPPV | Intervention Type: DEVICE; Name: NHFOV; Assigned to Arm(s): NHFOV | Intervention Type: DEVICE; Name: NCPAP; Assigned to Arm(s): NCPAP | Intervention Type: DEVICE; Name: NIPPV; Assigned to Arm(s): NIPPV

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Analysis of the Directional Spread of Geographic Atrophy (GA) in Patients With Age-related Macular Degeneration (AMD)
Brief Summary: Age-related macular degeneration (AMD) is the leading cause of irreversible blindness in industrial countries. In the late stages of the disease, neovascular changes or the development of geographic atrophy (GA) may induce severe visual loss. GA is characterized by the development of areas of outer retinal atrophy with continuous spread over time that is corresponded to an visual field defect for the patient. The pathogenesis is still incompletely understood. Despite the break-through in the treatment of neovascular AMD by intravitreally administrated vascular endothelial growths factor (VEGF) inhibitors, there is yet no treatment available to slow down or halt the disease process in GA. We and others have demonstrated that the total GA area progression shows large differences between patients. Potential factors influencing differential progression have been intensely studied: While neither systemic nor genetic factors have been shown to influence GA progression, ocular characteristics such as GA baseline size or phenotypic features of fundus autofluorescence (FAF) abnormalities have been identified as risk characteristics for increased GA progression. While these previous studies have mainly focused on the characterization of total GA area progression, topographic directional spread has not been analyzed and relevant predictive markers are yet unknown. There may be large differences in the local GA progression. The primary objective of this study is to identify specific characteristics, for the local GA progression. The knowledge of such risk factors may help to better understand the pathogenesis of GA. The identification of predictive markers will allow for better prognostic assessment of the individual disease process. The DSGA study is the extension trial of the FAM (Fundus Autofluorescence in Age-related Macular Degeneration) study (NCT00393692).


Options:
A: Intervention Type: DRUG; Name: rhuFab V2 (ranibizumab); Assigned to Arm(s): N/A
B: Arm Label: Ozanimod 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: Ozanimod, Drug: Interferon beta-1a placebo | Arm Label: Ozanimod1 mg; Type: EXPERIMENTAL; Interventions: Drug: Ozanimod, Drug: Interferon beta-1a placebo | Arm Label: Interferon β-1a; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ozanimod placebo, Drug: Interferon beta-1a | Intervention Type: DRUG; Name: Ozanimod; Assigned to Arm(s): Ozanimod 0.5 mg, Ozanimod1 mg | Intervention Type: DRUG; Name: Ozanimod placebo; Assigned to Arm(s): Interferon β-1a | Intervention Type: DRUG; Name: Interferon beta-1a; Assigned to Arm(s): Interferon β-1a | Intervention Type: DRUG; Name: Interferon beta-1a placebo; Assigned to Arm(s): Ozanimod 0.5 mg, Ozanimod1 mg
C: Intervention Type: DRUG; Name: rhuFab V2 (ranibizumab); Assigned to Arm(s): N/A
D: N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effectiveness of Core Stability Exercises on Abdominal Deep Muscles in Colorectal Cancer Survivors
Brief Summary: The purpose of this study is to determine the effects of physical training program to improve deep stabilizer muscle in colorectal cancer survivors


Options:
A: Arm Label: Exercise Counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Physical activity counseling | Arm Label: Contact Control; Type: PLACEBO_COMPARATOR; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Physical activity counseling; Assigned to Arm(s): Exercise Counseling
B: Arm Label: core stability; Type: EXPERIMENTAL; Interventions: Other: core stability | Arm Label: control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: core stability; Assigned to Arm(s): core stability
C: Arm Label: Physical activity intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Physical activity | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Physical activity; Assigned to Arm(s): Physical activity intervention
D: Arm Label: Soccer Training; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Soccer training | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Soccer training; Assigned to Arm(s): Soccer Training

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effectiveness of Core Stability Exercises on Abdominal Deep Muscles in Colorectal Cancer Survivors
Brief Summary: The purpose of this study is to determine the effects of physical training program to improve deep stabilizer muscle in colorectal cancer survivors


Options:
A: Arm Label: Yoga Group A: Minimum Exposure; Type: EXPERIMENTAL; Interventions: Other: Yoga | Arm Label: Yoga Group B: Medium Exposure; Type: EXPERIMENTAL; Interventions: Other: Yoga | Arm Label: Yoga Group C: Maximum Exposure; Type: EXPERIMENTAL; Interventions: Other: Yoga | Intervention Type: OTHER; Name: Yoga; Assigned to Arm(s): Yoga Group A: Minimum Exposure, Yoga Group B: Medium Exposure, Yoga Group C: Maximum Exposure
B: Arm Label: Wait-list control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Lifestyle counseling; Type: EXPERIMENTAL; Interventions: Behavioral: behavioral dietary and exercise intervention | Intervention Type: BEHAVIORAL; Name: behavioral dietary and exercise intervention; Assigned to Arm(s): Lifestyle counseling
C: Arm Label: core stability; Type: EXPERIMENTAL; Interventions: Other: core stability | Arm Label: control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: core stability; Assigned to Arm(s): core stability
D: Arm Label: dietary; Type: EXPERIMENTAL; Interventions: Behavioral: Dietary | Arm Label: physical activity; Type: EXPERIMENTAL; Interventions: Behavioral: Physical activity | Arm Label: dietary and physical activity; Type: EXPERIMENTAL; Interventions: Behavioral: Dietary, Behavioral: Physical activity | Arm Label: usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Dietary; Assigned to Arm(s): dietary, dietary and physical activity | Intervention Type: BEHAVIORAL; Name: Physical activity; Assigned to Arm(s): dietary and physical activity, physical activity

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Multicenter, Randomized, Single-Blind, Dose-Ranging, Crossover Study to Evaluate the Safety and Efficacy of Intravenous Administration of CINRYZE® (C1 Esterase Inhibitor [Human]) for the Prevention of Angioedema Attacks in Children 6 to 11 Years of Age With Hereditary Angioedema
Brief Summary: Primary Objective - To assess the relative efficacy of two dose levels of CINRYZE (500 Units and 1000 Units) administered by intravenous (IV) injection every 3 or 4 days to prevent angioedema attacks in children 6 to 11 years of age with hereditary angioedema (HAE).

Secondary Objectives - To assess the safety and tolerability, characterize the pharmacokinetics (PK) and pharmacodynamics (PD), and assess the immunogenicity of two dose levels of CINRYZE administered by IV injection in children 6 to 11 years of age with HAE.


Options:
A: Arm Label: 500/1000; Type: EXPERIMENTAL; Interventions: Biological: CINRYZE 500, Biological: CINRYZE 1000 | Arm Label: 1000/500; Type: EXPERIMENTAL; Interventions: Biological: CINRYZE 500, Biological: CINRYZE 1000 | Intervention Type: BIOLOGICAL; Name: CINRYZE 500; Assigned to Arm(s): 1000/500, 500/1000 | Intervention Type: BIOLOGICAL; Name: CINRYZE 1000; Assigned to Arm(s): 1000/500, 500/1000
B: Arm Label: Open-label C1INH-nf; Type: EXPERIMENTAL; Interventions: Biological: C1 esterase inhibitor [human] (C1INH-nf) | Intervention Type: BIOLOGICAL; Name: C1 esterase inhibitor [human] (C1INH-nf); Assigned to Arm(s): Open-label C1INH-nf
C: Arm Label: Part 1: BCX7353 350 mg once daily; Type: EXPERIMENTAL; Interventions: Drug: BCX7353 | Arm Label: Parts 2 and 3: BCX7353 250 mg once daily; Type: EXPERIMENTAL; Interventions: Drug: BCX7353 | Arm Label: Parts 2 and 3: BCX7353 125 mg once daily; Type: EXPERIMENTAL; Interventions: Drug: BCX7353 | Arm Label: Parts 1, 2 and 3: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Part 3: BCX7353 62.5 mg once daily; Type: EXPERIMENTAL; Interventions: Drug: BCX7353 | Intervention Type: DRUG; Name: BCX7353; Assigned to Arm(s): Part 1: BCX7353 350 mg once daily, Part 3: BCX7353 62.5 mg once daily, Parts 2 and 3: BCX7353 125 mg once daily, Parts 2 and 3: BCX7353 250 mg once daily | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Parts 1, 2 and 3: Placebo
D: Arm Label: CSL312; Type: EXPERIMENTAL; Interventions: Biological: CSL312 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: BIOLOGICAL; Name: CSL312; Assigned to Arm(s): CSL312 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Study of the Efficacy and Safety of FG-4592 in the Treatment of Anemia in Incident-Dialysis Patients
Brief Summary: The purpose of this study is to determine whether roxadustat is safe and effective in the treatment of anemia in participants who have just begun dialysis treatment for ESRD.


Options:
A: Arm Label: Roxadustat; Type: EXPERIMENTAL; Interventions: Drug: Roxadustat | Arm Label: Epoetin Alfa; Type: ACTIVE_COMPARATOR; Interventions: Drug: Epoetin Alfa | Intervention Type: DRUG; Name: Roxadustat; Assigned to Arm(s): Roxadustat | Intervention Type: DRUG; Name: Epoetin Alfa; Assigned to Arm(s): Epoetin Alfa
B: Arm Label: Molidustat (BAY85-3934); Type: EXPERIMENTAL; Interventions: Drug: Molidustat (BAY85-3934) | Intervention Type: DRUG; Name: Molidustat (BAY85-3934); Assigned to Arm(s): Molidustat (BAY85-3934)
C: Arm Label: Arm A + E (Participants on HD): Roxadustat Only, No Iron; Type: EXPERIMENTAL; Interventions: Drug: Roxadustat | Arm Label: Arm B (Participants on HD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mg; Type: EXPERIMENTAL; Interventions: Drug: Roxadustat, Drug: Oral Iron | Arm Label: Arm C (Participants on HD): IV Iron (Ferric Gluconate Complex in Sucrose or Equivalent) 60 mg; Type: EXPERIMENTAL; Interventions: Drug: Roxadustat, Drug: IV Iron | Arm Label: Arm D (Participants on PD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mg; Type: EXPERIMENTAL; Interventions: Drug: Roxadustat, Drug: Oral Iron | Intervention Type: DRUG; Name: Roxadustat; Assigned to Arm(s): Arm A + E (Participants on HD): Roxadustat Only, No Iron, Arm B (Participants on HD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mg, Arm C (Participants on HD): IV Iron (Ferric Gluconate Complex in Sucrose or Equivalent) 60 mg, Arm D (Participants on PD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mg | Intervention Type: DRUG; Name: Oral Iron; Assigned to Arm(s): Arm B (Participants on HD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mg, Arm D (Participants on PD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mg | Intervention Type: DRUG; Name: IV Iron; Assigned to Arm(s): Arm C (Participants on HD): IV Iron (Ferric Gluconate Complex in Sucrose or Equivalent) 60 mg
D: Arm Label: HIF-PHI; Type: EXPERIMENTAL; Interventions: Drug: HIF-PHI | Arm Label: Epoetin alfa; Type: ACTIVE_COMPARATOR; Interventions: Drug: Epoetin Alfa | Intervention Type: DRUG; Name: HIF-PHI; Assigned to Arm(s): HIF-PHI | Intervention Type: DRUG; Name: Epoetin Alfa; Assigned to Arm(s): Epoetin alfa

Answer: A